10-Q: Soligenix Q3 2025: Nasdaq Compliance & R&D Surge

Soligenix, Inc. reported increased net losses in Q3 2025, driven by higher R&D expenses, but regained Nasdaq compliance through a recent public offering.

Summary

• Net loss increased to $2,530,947 for the three months ended September 30, 2025, compared to $1,719,381 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $8,184,191, compared to $5,279,210 for the same period in 2024.
• Research and development expenses significantly increased to $1,583,879 for the three months ended September 30, 2025 (from $968,689 in 2024) and $5,202,573 for the nine months (from $2,564,887 in 2024), primarily due to the second confirmatory Phase 3 CTCL trial and Phase 2 BD study.
• Regained compliance with Nasdaq's minimum stockholders' equity requirement, reporting $7,597,976 as of September 30, 2025, following a $7.5 million public offering.
• Cash and cash equivalents increased to $10,525,335 as of September 30, 2025, from $7,819,514 at December 31, 2024.
• Patient enrollment for the confirmatory Phase 3 FLASH2 study of HyBryte in CTCL began in December 2024, with top-line results anticipated in the second half of 2026.
• Completed the Phase 2a proof-of-concept study for SGX945 (dusquetide) in Behcet's Disease (BD), demonstrating safety and biological efficacy.
• Received Orphan Drug designation from the FDA for SGX945 (dusquetide) in BD in August 2025.
• The first Data Monitoring Committee meeting for the confirmatory Phase 3 HyBryte study concluded no safety concerns in October 2025.

Sentiment

Score: 5

Explanation: The company reported increased net losses and R&D expenses, indicating a higher burn rate. However, it successfully regained Nasdaq compliance through a public offering and made notable progress in its clinical pipeline, including positive interim results for HyBryte and completion of a Phase 2a study for SGX945. The FDA's preference for a different HyBryte study design introduces some uncertainty for U.S. approval, balancing the positive developments.

Positives

• Regained compliance with Nasdaq's minimum stockholders' equity requirement, with stockholders' equity at $7,597,976 as of September 30, 2025.
• Cash and cash equivalents increased by $2,705,821 to $10,525,335 as of September 30, 2025.
• Completed a public offering on September 29, 2025, raising approximately $7.5 million gross proceeds.
• Patient enrollment for the confirmatory Phase 3 FLASH2 study of HyBryte in CTCL began in December 2024.
• Positive interim results from an ongoing open-label investigator-initiated study (IIS) for HyBryte in CTCL showed 75% of patients achieved "Treatment Success" after 18 weeks.
• Completed Phase 2a proof-of-concept study for SGX945 (dusquetide) in Behcet's Disease, demonstrating safety and biological efficacy.
• Received Orphan Drug designation from the FDA for SGX945 (dusquetide) in BD in August 2025.
• Successfully completed manufacturing process transfer for synthetic hypericin active ingredient with Sterling Pharma Solutions Limited in July 2025.
• The Data Monitoring Committee for the confirmatory Phase 3 HyBryte study found no safety concerns in October 2025.
• Fully repaid and terminated the $20 million convertible debt financing agreement with Pontifax in February 2025, incurring no prepayment penalties.

Negatives

• Net loss increased to $2,530,947 for the three months ended September 30, 2025, compared to $1,719,381 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $8,184,191, compared to $5,279,210 for the same period in 2024.
• Operating expenses increased significantly, with R&D up by $615,190 for the three months and $2,637,686 for the nine months.
• No grant revenue was recorded for the three and nine months ended September 30, 2025, compared to $119,371 in revenue for the nine months ended September 30, 2024.
• Interest income decreased for the three months ended September 30, 2025, due to lower cash balances prior to the public offering.
• Previously received a Nasdaq notice of non-compliance with the minimum stockholders' equity requirement on August 15, 2025.
• The FDA expressed a preference for a longer duration comparative study over a placebo-controlled trial for HyBryte, leading to continued discussions while initiating the EMA-accepted FLASH2 study.
• A second Phase 3 clinical trial of SGX942 (dusquetide) in oral mucositis is required for marketing authorization, and the company is seeking a partner for continued development.

Risks

• Uncertainty as to whether product candidates will be sufficiently safe and effective to support regulatory approvals.
• Inherent uncertainty in developing therapeutics and vaccines, and manufacturing and conducting preclinical and clinical trials.
• Ability to obtain future financing or funds when needed, either through capital raises, incurrence of debt, or strategic partnerships.
• Ability to secure government grants or contracts to support vaccine development.
• Ability to maintain listing on The Nasdaq Capital Market and meet its listing requirements.
• Product development and commercialization efforts may be reduced or discontinued due to difficulties or delays in clinical trials or lack of progress/positive results from R&D.
• Possibility that products under development may not gain market acceptance.
• Expectations about potential market sizes and market participation potential for product candidates may not be realized.
• Expected revenues (including sales, milestone payments, and royalty revenues) from product candidates and related commercial agreements may not be realized.
• Ability of manufacturing partners to supply clinical or commercial supplies in a safe, timely, and regulatory compliant manner, and to address regulatory issues.
• Competition existing today or that may arise in the future, including the possibility of superior technologies or products.
• The effect that global pathogens (e.g., COVID-19) could have on financial markets, materials sourcing, service providers, patients, clinical study sites, governments, and population.
• Shareholders may suffer substantial dilution related to issued pre-funded warrants, common stock warrants, options, and convertible notes.
• The sale, or even the possibility of the sale, of shares underlying pre-funded warrants, common stock warrants, options, and convertible promissory notes could adversely affect the market price or ability to obtain future financing.

Future Outlook

The company anticipates top-line results for the Phase 3 FLASH2 study of HyBryte in CTCL in the second half of 2026. It plans to continue discussions with the FDA on modifying the development path for HyBryte to address their feedback for a longer duration comparative study. Development plans include expanding synthetic hypericin (SGX302) into psoriasis with a Phase 2a clinical trial, designing a second Phase 3 clinical trial for SGX942 (dusquetide) in oral mucositis while seeking a partner, and conducting a Phase 2a clinical trial for SGX945 in Behcet's Disease. The company will continue developing its ThermoVax heat stabilization platform for various vaccine programs with government or non-governmental organization funding support. Management believes it has sufficient resources to support development activities and meet obligations for at least the next twelve months, and plans to pursue additional government funding, business development opportunities, and strategic alternatives.

Management Comments

• "Management believes that the Company has sufficient resources to support development activities, business operations, and meet its obligations for at least the next twelve months from issuance of these financial statements in this Quarterly Report on Form 10-Q."
• "We believe we have since regained compliance with the Stockholders Equity Requirement via a completed public offering on September 29, 2025 with total gross proceeds to us of approximately $7.5 million before deducting commissions and other estimated offering expenses of approximately $560,000."
• "While discussions have been collaborative, the FDA has expressed a preference for a longer duration comparative study over a placebo-controlled trial [for HyBryte]."
• "Given the shorter time to potential commercial revenue and the similar trial design to the first FLASH study afforded by the EMA accepted protocol, we determined to initiate the FLASH2 study in support of worldwide potential approval."
• "At the same time, we will continue discussions with the FDA on modifying the development path to adequately address their feedback."
• "The first Data Monitoring Committee meeting for our confirmatory Phase 3 study evaluating HyBryte in the treatment of CTCL concluded that there were no safety concerns with the ongoing Phase 3 study and that HyBryte has an acceptable safety profile that remains consistent with the safety data from all prior clinical studies."

Industry Context

Soligenix operates in the late-stage biopharmaceutical sector, focusing on rare diseases and unmet medical needs. Its Specialized BioTherapeutics segment addresses conditions like CTCL, psoriasis, oral mucositis, and Behcet's Disease, areas often characterized by limited or suboptimal treatment options. The Public Health Solutions segment aligns with global health security priorities by developing vaccines for biodefense and infectious diseases, often supported by government funding. The ThermoVax platform is a notable innovation addressing the critical industry challenge of vaccine cold chain requirements, which could significantly reduce global vaccine waste. The company's strategy of pursuing Orphan Drug and Fast Track designations for its candidates is a common and effective approach in the rare disease space to accelerate development and gain market exclusivity. The regulatory feedback requiring additional Phase 3 trials for some candidates underscores the stringent approval environment in the pharmaceutical industry.

Comparison to Industry Standards

• HyBryte for CTCL: Positions itself as a potentially safer alternative to current unapproved therapies like PUVA, which uses carcinogenic UV light and mutagenic Psoralen, by utilizing safe visible light to avoid severe adverse effects including secondary skin cancers.
• SGX302 for Psoriasis: Aims to offer a safer photodynamic therapy by using visible light, avoiding the risks of secondary malignancies and serious infections associated with UV light exposure or systemic immunosuppressive treatments used in psoriasis.
• SGX942 for Oral Mucositis: Targets an area of unmet medical need with no currently FDA-approved drug therapies. The Phase 2 study's observed 50% reduction in median duration of severe oral mucositis (67% in aggressive chemoradiation patients) represents a clinically meaningful improvement compared to the lack of approved alternatives.
• SGX945 for Behcet's Disease: Offers a novel approach to treating aphthous ulcers, a major symptom, distinct from the only approved maintenance therapy, apremilast, which is associated with high cost and side effects.
• ThermoVax platform: Addresses a significant global health challenge by potentially eliminating the need for cold chain production, transportation, and storage for Alum-adjuvanted vaccines, which could drastically reduce vaccine waste compared to standard refrigerated vaccines.
• CiVax (COVID-19 vaccine): Preclinical efficacy results suggest that a CiVax booster combined with a primary adenovirus vaccine induced broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series (e.g., Moderna, Pfizer) in humans, indicating a potentially superior or complementary vaccine strategy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced dilution from the recent public offering and face potential future dilution from outstanding warrants and options. The increased net losses could negatively impact share value, but regaining Nasdaq compliance provides stability. Future value is highly dependent on clinical success and securing additional funding.
• Employees: Continued R&D activities and business operations support employment. Share-based compensation is a component of remuneration.
• Customers (future patients): Progress in clinical trials for HyBryte (CTCL), SGX302 (psoriasis), SGX942 (oral mucositis), and SGX945 (Behcet's Disease) offers potential new treatment options for conditions with unmet medical needs or suboptimal existing therapies.
• Suppliers/Partners: Ongoing collaborations, such as with Sterling Pharma Solutions for manufacturing, indicate continued business relationships.
• Creditors: The full repayment of the convertible debt to Pontifax in February 2025 reduces the company's debt burden and associated interest expenses.

Next Steps

• Anticipate top-line results for the Phase 3 FLASH2 study of HyBryte in CTCL in the second half of 2026.
• Continue discussions with the FDA on potential modifications to the HyBryte development path to adequately address their feedback.
• Conduct a Phase 2a clinical trial for SGX302 in psoriasis.
• Design a second Phase 3 clinical trial for SGX942 in oral mucositis and attempt to identify a potential partner(s) to continue this development program.
• Conduct a Phase 2a clinical trial for SGX945 in Behcet's Disease.
• Continue development of the ThermoVax heat stabilization platform technology for various vaccine programs (RiVax, filoviruses, CiVax) with U.S. government or non-governmental organization funding support.
• Continue to apply for and secure additional government funding for both Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts, and/or procurements.
• Pursue business development opportunities for pipeline programs and explore all strategic alternatives, including but not limited to merger/acquisition strategies.
• Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.
• The Data Monitoring Committee will conduct one interim analysis for the FLASH2 study when approximately 60% of the total subjects have completed the primary endpoint evaluation.

Key Dates

Recommendation

While Soligenix has made significant clinical progress with HyBryte and SGX945, successfully addressed Nasdaq compliance, and improved its cash position through a recent offering, the substantial increase in net losses and R&D expenses indicates a high burn rate. The FDA's preference for a different HyBryte study design introduces regulatory uncertainty for the U.S. market. The company's future success heavily relies on positive clinical trial outcomes and securing additional funding or partnerships, which are inherently risky. Given the mixed financial performance and ongoing clinical and regulatory hurdles, a "hold" recommendation is appropriate for investors to monitor further developments.

Keywords

biopharmaceutical, rare diseases, CTCL, HyBryte, SGX301, cutaneous T-cell lymphoma, Phase 3 clinical trial, FLASH2, dusquetide, SGX942, oral mucositis, Behcet's Disease, SGX945, ThermoVax, vaccines, ricin toxin, RiVax, Ebola, Marburg, COVID-19, Nasdaq compliance, public offering, R&D, biotech, Orphan Drug, Fast Track, synthetic hypericin, psoriasis, SGX302, clinical development, drug development, financial results, SEC filing, SNGX